HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, CA. Kadima, a profitable clinic specializing in interventional psychiatry, will serve as the clinical model for HOPE's nationwide treatment network. The institute is a leading research site for CNS and psychedelic therapies, offering treatments including ketamine, Spravato, and TMS for conditions like suicidal depression and PTSD.
Dr. David Feifel, Kadima's founder and a recognized expert in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer post-acquisition. The acquisition is expected to be accretive to revenue and EBITDA for both NRx and HOPE, subject to closing conditions and financing finalization.
HOPE Therapeutics, una controllata di NRx Pharmaceuticals (NASDAQ:NRXP), ha firmato un accordo definitivo per acquisire il Kadima Neuropsychiatry Institute di La Jolla, CA. Kadima, una clinica redditizia specializzata in psichiatria interventistica, sarà il modello clinico per la rete di trattamento nazionale di HOPE. L'istituto è un centro di ricerca di riferimento per le terapie del sistema nervoso centrale e psichedeliche, offrendo trattamenti come ketamina, Spravato e TMS per condizioni quali depressione suicidaria e PTSD.
Il dott. David Feifel, fondatore di Kadima ed esperto riconosciuto in psichiatria interventistica, entrerà in HOPE come Chief Medical Innovation Officer dopo l'acquisizione. L'acquisizione dovrebbe incrementare ricavi ed EBITDA sia per NRx che per HOPE, subordinatamente alle condizioni di chiusura e al completamento del finanziamento.
HOPE Therapeutics, una subsidiaria de NRx Pharmaceuticals (NASDAQ:NRXP), ha firmado un acuerdo definitivo para adquirir el Kadima Neuropsychiatry Institute en La Jolla, CA. Kadima, una clínica rentable especializada en psiquiatría intervencionista, servirá como modelo clínico para la red nacional de tratamientos de HOPE. El instituto es un sitio líder en investigación de terapias del SNC y psicodélicas, ofreciendo tratamientos como ketamina, Spravato y TMS para condiciones como depresión suicida y PTSD.
El Dr. David Feifel, fundador de Kadima y reconocido experto en psiquiatría intervencionista, se unirá a HOPE como Chief Medical Innovation Officer tras la adquisición. Se espera que la adquisición sea positiva para los ingresos y EBITDA tanto de NRx como de HOPE, sujeto a condiciones de cierre y finalización del financiamiento.
HOPE Therapeutics는 NRx Pharmaceuticals (NASDAQ:NRXP)의 자회사로서 캘리포니아 라호야에 위치한 Kadima Neuropsychiatry Institute를 인수하는 확정 계약을 체결했습니다. Kadima는 수익성 있는 중재 정신과 전문 클리닉으로, HOPE의 전국 치료 네트워크의 임상 모델 역할을 하게 됩니다. 이 연구소는 중추신경계 및 사이키델릭 치료 연구의 선도 기관으로, 자살 우울증과 PTSD 같은 질환에 대해 케타민, Spravato, TMS 치료를 제공합니다.
Kadima의 창립자이자 중재 정신과 분야의 권위자인 Dr. David Feifel은 인수 후 HOPE의 최고 의료 혁신 책임자(Chief Medical Innovation Officer)로 합류할 예정입니다. 이번 인수는 종결 조건 및 자금 조달 완료에 따라 NRx와 HOPE 모두의 매출과 EBITDA 증가에 기여할 것으로 기대됩니다.
HOPE Therapeutics, une filiale de NRx Pharmaceuticals (NASDAQ:NRXP), a signé un accord définitif pour acquérir le Kadima Neuropsychiatry Institute situé à La Jolla, en Californie. Kadima, une clinique rentable spécialisée en psychiatrie interventionnelle, servira de modèle clinique pour le réseau national de traitement de HOPE. L'institut est un site de recherche de premier plan pour les thérapies du système nerveux central et psychédéliques, proposant des traitements tels que la kétamine, Spravato et la TMS pour des affections comme la dépression suicidaire et le SSPT.
Le Dr David Feifel, fondateur de Kadima et expert reconnu en psychiatrie interventionnelle, rejoindra HOPE en tant que Chief Medical Innovation Officer après l'acquisition. Cette acquisition devrait être bénéfique pour le chiffre d'affaires et l'EBITDA de NRx et de HOPE, sous réserve des conditions de clôture et de la finalisation du financement.
HOPE Therapeutics, eine Tochtergesellschaft von NRx Pharmaceuticals (NASDAQ:NRXP), hat eine verbindliche Vereinbarung zum Erwerb des Kadima Neuropsychiatry Institute in La Jolla, Kalifornien, unterzeichnet. Kadima, eine profitable Klinik, die sich auf interventionelle Psychiatrie spezialisiert hat, wird als klinisches Modell für das landesweite Behandlungsnetzwerk von HOPE dienen. Das Institut ist eine führende Forschungseinrichtung für ZNS- und psychedelische Therapien und bietet Behandlungen wie Ketamin, Spravato und TMS für Erkrankungen wie suizidale Depression und PTBS an.
Dr. David Feifel, Gründer von Kadima und anerkannter Experte für interventionelle Psychiatrie, wird nach der Übernahme als Chief Medical Innovation Officer zu HOPE stoßen. Die Übernahme wird voraussichtlich den Umsatz und das EBITDA sowohl von NRx als auch von HOPE steigern, vorbehaltlich der Abschlussbedingungen und der endgültigen Finanzierung.
- Acquisition expected to be accretive to revenue and EBITDA
- Target company (Kadima) is currently profitable with forecasted growth
- Acquisition provides access to leading research capabilities in CNS and psychedelic trials
- Strategic expansion into interventional psychiatry market with established clinical model
- Acquisition still subject to financing and closing conditions
- Financial terms and transaction details not disclosed
Insights
NRXP's acquisition of Kadima Neuropsychiatry Institute strategically positions the company in the growing interventional psychiatry market, with potential for revenue growth and clinical trial capabilities.
The announced acquisition of Kadima Neuropsychiatry Institute represents a significant strategic pivot for NRx Pharmaceuticals as it expands beyond traditional biopharma into the clinical services space through its HOPE Therapeutics subsidiary. This acquisition provides three key strategic advantages:
First, it establishes an immediate revenue-generating model - Kadima is described as profitable with projected continued growth. This is particularly valuable for NRx, which as a clinical-stage biopharma typically lacks substantial revenue streams.
Second, the acquisition provides NRx with a proven clinical model for its planned nationwide network of interventional psychiatry clinics. Kadima offers treatments including ketamine, Spravato, and transcranial magnetic stimulation (TMS) for depression, PTSD, and other CNS disorders - positioning HOPE in the rapidly growing market for alternative mental health treatments.
Third, and perhaps most strategically valuable, the acquisition brings in Dr. David Feifel as Chief Medical Innovation Officer. Dr. Feifel's credentials - including membership in the American College of Neuropharmacology and leadership in the Clinical TMS Society - bring scientific credibility, while his experience as a lead investigator on numerous clinical trials provides NRx with enhanced capabilities to conduct research on its own pipeline candidates.
The acquisition also positions NRx/HOPE to participate in the emerging psychedelic medicine space, as Kadima has served as a lead site for major clinical trials in this area. This creates potential synergies with NRx's existing CNS-focused drug development programs.
While financial details are pending ("subject to satisfaction of standard closing conditions and finalization of financing"), the explicit statement that the acquisition is "expected to be accretive to revenue and EBITDA" suggests this move will positively impact NRx's financial position in the near-term, even as it builds toward longer-term strategic goals in mental healthcare delivery.
- Kadima Neuropsychiatry Institute in
La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwide - Kadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this space
- Dr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing
- Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE
Kadima is one of
Dr. Feifel will join HOPE as its first Chief Medical Innovation Officer ("CMIO") upon closing of the acquisition. A nationally recognized expert in interventional psychiatry, Dr. Feifel's distinctions include serving as an elected member of the American College of Neuropharmacology, peer-elected inclusion in "Best Doctors in America," and citation in the Castle Connolly list of "Top Doctors" — a recognition given to only 10 psychiatrists in
"The signing of a definitive agreement to acquire Kadima marks a pivotal moment in the execution of our strategy to redefine mental healthcare access and delivery of care through HOPE Therapeutics," said Dr. Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE . "Dr. David Feifel is a true pioneer in interventional psychiatry and we are honored to have him join our leadership team. With his guidance, we are accelerating the buildout of a world-class clinic network that integrates cutting-edge science with community-based care."
The planned acquisition of Kadima is subject to satisfaction of standard closing conditions and finalization of financing. Further details on the transaction will be disclosed at that time.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (preservative free IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
For further information:
Matthew Duffy | Brian Korb | |
Co-CEO, Hope Therapeutics, Inc. | Managing Partner, ASTR Partners | |
Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-nasdaqnrxp-announce-signing-of-definitive-agreement-to-purchase-kadima-neuropsychiatry-institute-foundational-acquisition-for-the-hope-network-of-interventional-psychiatry-clinic-302453557.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the purpose of NRXP's acquisition of Kadima Neuropsychiatry Institute?
How will the Kadima acquisition impact NRXP's financial performance?
Who is Dr. David Feifel and what role will he play at NRXP?
What treatments does Kadima Neuropsychiatry Institute offer?
Is the NRXP-Kadima acquisition deal final?
